Table 4.
Comparison of mean change in efficacy variables in patients with associated erectile dysfunction between both groups
| Tadalafil (N = 17) | Tamsulosin (N = 13) | P value | |||||
|---|---|---|---|---|---|---|---|
| Baseline | 12 weeks | Change from baseline | Baseline | 12 weeks | Change from baseline | ||
| Qmax (ml/sec) | 12.38 | 14.55 | +2.17 | 13.62 | 17.56 | +3.94 | 0.0001* |
| PVR (ml) | 46.1 | 35.2 | -10.9 | 65.7 | 20.3 | -45.4 | 0.0001* |
| IPSS | 14.0 | 13.18 | -0.82 | 14.77 | 11.62 | -3.15 | 0.334 |
| IPSS QoL | 2.71 | 2.47 | -0.24 | 3.0 | 2.38 | -0.62 | 0.238 |
| SHIM | 12.65 | 15.53 | +2.88 | 13.38 | 14.62 | +1.24 | 0.028* |
Qmax – maximum flow rate, PVR – postvoid residual urine, IPSS – International Prostate Symptom Score, IPSS QoL – International Prostate Symptom Score Quality of life, SHIM – Sexual Health Inventory for Men